Dynamic contrast‐enhanced MRI in advanced nonsmall‐cell lung cancer patients treated with first‐line bevacizumab, gemcitabine, and cisplatin

To investigate dynamic contrast‐enhanced (DCE) magnetic resonance imaging (MRI) of advanced nonsmall‐cell lung cancer (NSCLC) patients treated with the antiangiogenic agent bevacizumab combined with gemcitabine and cisplatin as first‐line treatment.

[1]  Chii‐Ming Lee,et al.  Correlation between pancreatic microcirculation and type 2 diabetes in patients with coronary artery disease: dynamic contrast-enhanced MR imaging. , 2009, Radiology.

[2]  R. Wahl,et al.  From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors , 2009, Journal of Nuclear Medicine.

[3]  David W Townsend,et al.  Time Course of Early Response to Chemotherapy in Non–Small Cell Lung Cancer Patients with 18F-FDG PET/CT , 2007, Journal of Nuclear Medicine.

[4]  Robert Gray,et al.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.

[5]  Walter H Backes,et al.  Dynamic contrast-enhanced MR imaging kinetic parameters and molecular weight of dendritic contrast agents in tumor angiogenesis in mice. , 2005, Radiology.

[6]  G. Giaccone,et al.  Evaluation of KRAS Mutations, Angiogenic Biomarkers, and DCE-MRI in Patients with Advanced Non–Small-Cell Lung Cancer Receiving Sorafenib , 2011, Clinical Cancer Research.

[7]  L R Schad,et al.  Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging. , 1991, Journal of computer assisted tomography.

[8]  B. Taouli,et al.  Timing bolus dynamic contrast‐enhanced (DCE) MRI assessment of hepatic perfusion: Initial experience , 2009, Journal of magnetic resonance imaging : JMRI.

[9]  Risto A Kauppinen,et al.  Monitoring cytotoxic tumour treatment response by diffusion magnetic resonance imaging and proton spectroscopy , 2002, NMR in biomedicine.

[10]  Rakesh K. Jain,et al.  Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy , 2001, Nature Medicine.

[11]  R. Ramlau,et al.  Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  J R Griffiths,et al.  Clinical studies. , 2005, Advances in pharmacology.

[13]  A. Rossi,et al.  The role of bevacizumab in the treatment of non-small cell lung cancer: current indications and future developments. , 2007, The oncologist.

[14]  Benjamin M Yeh,et al.  Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Joseph V. Hajnal,et al.  Registration and Subtraction of Serial Magnetic Resonance Images of the Brain: Image Interpretation and Clinical Applications , 2001 .

[16]  J. Marcus,et al.  First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  Proton MR spectroscopy for monitoring early treatment response of breast cancer to neo-adjuvant chemotherapy. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  S. Zeger,et al.  Longitudinal data analysis using generalized linear models , 1986 .

[19]  H. Ahmadieh,et al.  Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. , 2009, Ophthalmology.

[20]  Jyh-Horng Chen,et al.  Angiogenic response of locally advanced breast cancer to neoadjuvant chemotherapy evaluated with parametric histogram from dynamic contrast-enhanced MRI. , 2004, Physics in medicine and biology.

[21]  Pieter Leffers,et al.  Monitoring Response to Antiangiogenic Therapy in Non–Small Cell Lung Cancer Using Imaging Markers Derived from PET and Dynamic Contrast-Enhanced MRI , 2011, The Journal of Nuclear Medicine.

[22]  Napoleone Ferrara,et al.  Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. , 2005, Cancer research.

[23]  N. Ferrara,et al.  The biology of VEGF and its receptors , 2003, Nature Medicine.

[24]  R. Brunelli.  Template Matching as Testing , 2009 .

[25]  Roberto Brunelli,et al.  Template Matching Techniques in Computer Vision: Theory and Practice , 2009 .

[26]  Carmel Hayes,et al.  Prediction of clinicopathologic response of breast cancer to primary chemotherapy at contrast-enhanced MR imaging: initial clinical results. , 2006, Radiology.

[27]  David M Jablons,et al.  Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  M. Christian,et al.  [New guidelines to evaluate the response to treatment in solid tumors]. , 2000, Bulletin du cancer.

[29]  A R Padhani,et al.  Commentary. Are current tumour response criteria relevant for the 21st century? , 2000, The British journal of radiology.

[30]  Bing Li,et al.  Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo , 1993, Nature.

[31]  A. Sandler,et al.  Epidermal Growth Factor Receptor Inhibitors and Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer , 2009, Clinical Cancer Research.

[32]  K Y Liang,et al.  Longitudinal data analysis for discrete and continuous outcomes. , 1986, Biometrics.

[33]  E. Voest,et al.  Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. , 2007, The oncologist.

[34]  D. Eberhard,et al.  Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. , 2000, Cancer research.

[35]  M. Knopp,et al.  Estimating kinetic parameters from dynamic contrast‐enhanced t1‐weighted MRI of a diffusable tracer: Standardized quantities and symbols , 1999, Journal of magnetic resonance imaging : JMRI.

[36]  L. Turnbull,et al.  Prognostic value of pre-treatment DCE-MRI parameters in predicting disease free and overall survival for breast cancer patients undergoing neoadjuvant chemotherapy. , 2009, European journal of radiology.

[37]  Geoff J M Parker,et al.  Imaging Tumor Vascular Heterogeneity and Angiogenesis using Dynamic Contrast-Enhanced Magnetic Resonance Imaging , 2007, Clinical Cancer Research.

[38]  R. Ramlau,et al.  Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  T. A. Smith,et al.  FDG uptake, tumour characteristics and response to therapy: A review , 1998, Nuclear medicine communications.